In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hybrigenics receives €1.4 million to develop inecalcitol

This article was originally published in Scrip

Executive Summary

Hybrigenicshas received €1.4 million from OSEO, a French governmental development agency, to develop inecalcitol for prostrate cancer. The refundable subsidy will help the French functional proteomics firm and developer of cancer therapies to fund Phase II clinical trials through to their expected completion in mid-2009, and for regulatory requirements for authorising therapeutic efficacy studies. The company is conducting a Phase II tolerance trial of inecalcitol in combination with Sanofi-Aventis's Taxotere (docetaxel) for hormone-refractory prostate cancer. The oral dose of 300mg showed excellent tolerance, said Hybrigenics, and treatment with 600mg has just begun. The funding contributes 47.3% to total spending needed for the trial.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts